Acasă › Cancer (toate tipurile) › Washington › Seattle
Studii clinice pentru Cancer (toate tipurile) în Seattle, WA
49 studii pentru Cancer (toate tipurile) caută participanți în și în jurul orașului Seattle (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
În curs de recrutareFaza 2/3
- Fred Hutchinson Cancer Center. /ID# 277939, Seattle
Registry Study for Radiation Therapy Outcomes
În curs de recrutareStudiu observațional
- University of Washington, Seattle
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
În curs de recrutareStudiu observațional
- Fred Hutchinson Cancer Center, Seattle
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
În curs de recrutareFaza 2/3
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center, Seattle
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
În curs de recrutareFaza 1
- Swedish Cancer Institute, Seattle
A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer
În curs de recrutare
- Seattle Children's Hospital, Seattle
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
În curs de recrutareFaza 3
- Fred Hutchinson Cancer Center ( Site 0106), Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
În curs de recrutareFaza 2
- Swedish Cancer Institute, Seattle
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
În curs de recrutareFaza 2/3
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Collection of Tissue Samples for Cancer Research
În curs de recrutareStudiu observațional
- Fred Hutchinson, Seattle
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
În curs de recrutareFaza 2
- Seattle Neuropsychiatric Treatment Center, Seattle
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
În curs de recrutareFaza 1
- Investigational Site Number: 400, Seattle
A Phase 1/1b Study of IAM1363 in HER2 Cancers
În curs de recrutareFaza 1
- Fred Hutchinson Cancer Center, Seattle
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
În curs de recrutareFaza 3
- Swedish Medical Center, Seattle
- VA Puget Sound Health Care System, Seattle
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
În curs de recrutareStudiu observațional
- University of Washington, Seattle
Prostate Active Surveillance Study
În curs de recrutareStudiu observațional
- Veterans Affairs Puget Sound Health Care System, Seattle
- University of Washington, Seattle
Project: Every Child for Younger Patients With Cancer
În curs de recrutareStudiu observațional
- Seattle Children's Hospital, Seattle
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
În curs de recrutareFaza 1/2
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
În curs de recrutareVoluntari sănătoși bineveniți
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
În curs de recrutareFaza 1
- Fred Hutchinson Cancer Center, Seattle
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
În curs de recrutareFaza 2
- Seattle Children's Hospital Research Foundation, Seattle
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
În curs de recrutareFaza 3
- Swedish Medical Center-Ballard Campus, Seattle
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- și încă 4
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
În curs de recrutareFaza 2
- Seattle Children's Hospital, Seattle
Resilience Mobile App for Teens and Young Adults With Cancer
În curs de recrutare
- Seattle Children's Hospital, Seattle
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
În curs de recrutareFaza 1
- Fred Hutchinson Cancer Center. /ID# 267940, Seattle
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
În curs de recrutareFaza 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
În curs de recrutareFaza 1
- GSK Investigational Site, Seattle
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
În curs de recrutareFaza 1/2
- Fred Hutchinson Cancer Center, Seattle
Childhood Cancer Survivor Study
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
- Seattle Children's Hospital, Seattle
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
În curs de recrutare
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
În curs de recrutareFaza 1/2
- Fred Hutchinson Cancer Center, Seattle
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
În curs de recrutareFaza 2/3
- University of Washington Medical Center /ID# 275866, Seattle
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
În curs de recrutareFaza 1/2
- Fred Hutchinson Cancer Center, Seattle
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
În curs de recrutareFaza 1/2
- University of Washington Medical Center, Seattle
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
În curs de recrutareFaza 2Voluntari sănătoși bineveniți
- Fred Hutchinson Cancer Centre, Seattle
Suprachoroidal Administration in Subjects With Metastases to the Choroid
În curs de recrutareFaza 2
- University of Washington, Seattle
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
În curs de recrutareFaza 1
- Fred Hutchinson Cancer Center, Seattle
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
În curs de recrutareFaza 2
- Seattle Children's Hospital, Seattle
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
În curs de recrutareStudiu observațional
- Seattle Children's Hospital, Seattle
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
În curs de recrutareFaza 2
- Swedish Cancer Institute, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
În curs de recrutareStudiu observațional
- Massive Bio SYNERGY-AI site, Seattle
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
În curs de recrutareFaza 1
- Fred Hutch Cancer Center, Seattle
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
În curs de recrutareStudiu observațional
- The Swedish Hospital, Seattle
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
În curs de recrutareFaza 1/2
- Fred Hutch Cancer Center, Seattle
A Study of NX-1607 in Adults With Advanced Malignancies
În curs de recrutareFaza 1
- Fred Hutchinson Cancer Center, Seattle
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
În curs de recrutareStudiu observațional
- Swedish Cancer Institute, Seattle
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
În curs de recrutareStudiu observațional
- University of Washington / Fred Hutchinson Cancer Center, Seattle
A Crowd Sourcing Platform for Patients With Cancer
În curs de recrutareStudiu observațional
- All4Cure, Seattle
AIMS Cancer Outcomes Study
În curs de recrutareStudiu observațional
- AIMS Institute, Seattle
Studii pentru Cancer (toate tipurile) în alte orașe
- Houston, TX121 studii
- New York City, NY110 studii
- Boston, MA86 studii
- Los Angeles, CA73 studii
- Nashville, TN65 studii
- Philadelphia, PA59 studii
- Durham, NC58 studii
- Washington, DC58 studii
- Chicago, IL51 studii
- Atlanta, GA49 studii
- Arlington, VA48 studii
- St. Louis, MO46 studii
Alte studii în Seattle
- Cancer pulmonar cu celule non-pătrate53 studii
- Cancer de prostată42 studii
- Leucemie mieloasă acută40 studii
- Cancer de sân39 studii
- Cancer metastatic39 studii
- Cancer colorectal34 studii
- Cancer pulmonar33 studii
- Cancer ovarian30 studii
- Mielom multiplu22 studii
- Sindroame mielodisplastice21 studii
- Leucemie limfoblastică acută21 studii
- Cancer de vezică urinară21 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.